ADURS 2017 Speakers  
Titles/Objectives  

Friday, February 24, 2017  

Michael Magnotti, MD, FACE, ECNU, Attending Endocrinologist - DEMS - New Jersey; Associate Clinical Professor - Rutgers NJ Medical School  
**Title:** The Management of Type 2 Diabetes: From Metformin to Insulin and Everything In Between  
**ACPE UAN:** 0128-9999-17-001-L01-P  
**CE:** 1.0 contact hours / Knowledge based CPE activity  
**Objectives:**  
1. Define the most appropriate times to initiate insulin therapy.  
2. Examine a reasonable method in which the non-insulin diabetes medications should be added to a patient’s medication regimen.  
3. Explain the potential benefits of the new to market basal insulins.  
4. Describe the most appropriate use of a combination of insulin and a GLP-1 agent, including the upcoming agents which combine both in a single injection.  
5. Identify situations in which it is appropriate to combine insulin with non-insulin agents.  

Rachel Boyer, PharmD, BCPS, Clinical Account Manager, Health Information Designs, LLC  
**Title:** A Comprehensive Approach to Cancer Management  
**ACPE UAN:** 0128-9999-17-002-L01-P  
**CE:** 1.0 contact hours / Knowledge based CPE activity  
**Objectives:**  
1. List reasons why cancer-related treatment is difficult to manage for healthcare coverage providers  
2. Identify resources available to provide clinical information for cancer-related treatment  
3. Devise a plan that integrates criteria for use into cancer-related treatment coverage  

Kay Lester, RPh, Pharmacist, Pharmacy Benefit Oversight; Vendor Drug Program; Texas Health and Human Services Commission; Brian Thompson, PharmD, DUR Coordinator, Office of Pharmacy Services, WV Bureau for Medical Services; and Monica Toohey, RPh, Pharmacist, NY State Medicaid Pharmacy Supervisor of Formulary Operations and Systems Interface, NY State DOH.  
**Title:** MCO & DUR: Different State Methodologies  
**ACPE UAN:** 0128-9999-17-004-L04-P  
**CE:** 1.0 contact hours / Knowledge based CPE activity  
**Objectives:**  
1. Examine the steady increase in Medicaid states moving from FFS to Managed Medicaid.  
2. Identify how many Medicaid states have contracts with MCOs.  
3. Outline gaps in prescription drug coverage when contracting with MCO for Medicaid benefits.  

James Roerig, PharmD, BCPP, Professor, Director Undergraduate Medical Education in Psychiatry & Psychiatry Clerkship Assistant Director, Psychiatry Residency Program, Department of Psychiatry and Behavioral Science, School of Medicine and Health Sciences, University of North Dakota  
**Title:** Treatment of Adult ADHD  
**ACPE UAN:** 0128-9999-017-004-L01-P  
**CE:** 1.0 contact hours / Knowledge based CPE activity  
**Objectives:**  
1. Identify criteria used to identify adult ADHD.  
2. Identify the different treatment options for adult ADHD.
3. Rank the treatments in terms of abuse potential.
4. Identify pro and con aspects of use of each of the treatments.
5. Describe relevant side effects for each treatment used to monitor therapy.

Charles Radis, DO, Rheumatologist, Maine Coast Memorial Hospital
Title: Immunotherapy in Rheumatology: Lowering Barriers to Effective Treatment in a Cost-Constrained World
ACPE UAN: 0128-9999-017-005-L01-P
CE: 1.5 contact hours / Knowledge based CPE activity
Objectives:
1. Explain the mechanism of action of Tumor Necrosis Factor (TNF) blockade, Interleukin-1 receptor (IL-1R) antagonism, B-cell depletion and selective inhibition of T cell lymphocyte activation in the treatment of rheumatoid arthritis.
2. Determine if the requirement for providers to prescribe two or more TNF blockers before approval of Rituximab or other immunotherapy, in patients failing initial treatment in rheumatoid arthritis supported by the evidence.
3. Explain where Xeljanz (tofacitinib citrate) fits into the formulary in the treatment of rheumatoid arthritis.
4. Determine if Rituximab should be first line treatment in the treatment of anti-neutrophil cytoplasmic antibody (ANCA) positive vasculitis.
5. Identify which systemic lupus erythematosus (SLE) patients are appropriate candidates for Benlysta (belimumab).

Jill Ratterman, DPh, Clinical Pharmacist, Oklahoma Health Care Authority
Title: Improving Patient Care in Hemophilia
ACPE UAN: 0128-9999-017-006-L04-P
CE: 0.5 contact hours / Knowledge based CPE activity
Objectives:
1. Explain the history of Oklahoma’s efforts in managing hemophilia
2. Examine the implementation of a provider based prior authorization through pharmacy hemophilia providers’ standards of care
3. Describe the prior authorization requirements for the extended half-life factor products

Michael Ouellette, RPh, Director of Provider Services, Change Healthcare
Title: Effective RetroDUR Interventions
ACPE UAN: 0128-9999-017-007-L04-P
CE: 0.5 contact hours / Knowledge based CPE activity
Objectives:
1. Review effective, actionable RetroDUR interventions.
2. Identify various type of interventions, both provider and member focused.
3. Examine options for how intervention results can be used to drive clinically meaningful actions.

Fury Fecondo, PharmD, Consultant Pharmacist, Delaware Healthcare Services
Title: State Roundtable - State Medicaid Programs - Part 1
ACPE UAN: 0128-9999-017-008-L04-P
CE: 1.25 contact hours / Knowledge based CPE activity
Objectives:
1. Examine retroDUR methodologies, processes, and outcomes of State Medicaid DUR initiatives.
2. Identify environmental factors that contribute to successes and failures of State Medicaid programs medication management initiatives.
3. Describe proposals for DUR initiatives based upon the proposal phase, implementation phase, program delivery and outcome evaluation phase.
Saturday, February 25, 2017

Thomas Frank, PharmD, BCPS, Director of Education and Research, Area Health Education Center Northeast

Title: New Drugs 2017
ACPE UAN: 0128-9999-017-009-L01-P
CE: 2.0 contact hours / Knowledge based CPE activity

Objectives:
1. Identify new trends in drug development.
2. List indications, pharmacology, adverse effects, and dosing.
3. Explain the role these products will play in the participant’s practice.
4. Describe the economic implication of these choices.
5. Examine products in the short-term pipeline that will be important to the practice of the participants.

Maria M. Lowe, PharmD, BCPS, Health Data & Drug Information Clinical Specialist, PatientsLikeMe

Title: Pipeline Preview 2017
ACPE UAN: 0128-9999-017-010-L01-P
CE: 1.5 contact hours / Knowledge based CPE activity

Objectives:
1. Describe recent trends in the FDA approval process.
2. Compare and contrast emerging pipeline agents with currently available therapeutic options.
3. Examine the expected generic availability of commonly used agents over the next two years.

Fury Fecondo, PharmD, Consultant Pharmacist, Delaware Healthcare Services

Title: State Roundtable - State Medicaid Programs - Part 2
ACPE UAN: 0128-9999-017-012-L04-P
CE: 1.25 contact hours / Knowledge based CPE activity

Objectives:
1. Examine retroDUR methodologies, processes, and outcomes of State Medicaid DUR initiatives.
2. Identify environmental factors that contribute to successes and failures of State Medicaid programs medication management initiatives.
3. Describe proposals for DUR initiatives based upon the proposal phase, implementation phase, program delivery and outcome evaluation phase.

Renee Hilliard, PharmD, CGP, Pharmacist, Center for Medicaid & CHIP Services; Centers for Medicare & Medicaid Services

Title: CMS Update
No CPE hours.
The 2017 ADURS Symposium is designed for pharmacists specializing in medication utilization within State Medicaid programs and is sponsored by the American Drug Utilization Review Society (ADURS) and the Nebraska Council for Continuing Pharmacy Education (NCCPE). NCCPE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Credit for courses must be earned by the participant. Participants will earn up to 12.5 contact hours of continuing pharmacy education (CPE) credits for attendance of the entire symposium.

In order to earn CPE credits, the participant must complete an on-line educational evaluation form for each CPE session they attend within 15 days from the end of the symposium. The evaluation will collect birthdates (MMDD) and NABP e-Profile ID numbers (to receive CPE credits, the attendee must have an NABP e-Profile ID number). For more information about NABP e-Profile IDs, please see http://www.nabp.net/programs/cpe-monitor/cpe-monitor-service/). ACPE CPE numbers and speaker objectives can be found in the program schedule. CPE credits will be sent to your NABP e-Profile within 45 days of the program date. For questions about CPE credits, please call NCCPE at (402) 420-1500.